MarketLens

What Were HCW Biologics' Key Developments in Q1 2026

3 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Were the Key Outcomes of Walmart's 2026 Shareholder Meeting

2 months ago

What Were the Key Takeaways from Resideo's J.P. Morgan Conference Presentation

3 months ago

What Were the Key Highlights from Beam's RBC Conference Presentation

3 months ago

What were the key takeaways from SEI's William Blair presentation

2 months ago

HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results

HCW Biologics reported Q2 2026 financial results and clinical development highlights for the three and six months ended June 30, 2026, covering its fusion immunotherapeutics pipeline for autoimmune di...

HCWB

Stock News•1 week ago

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Aptevo Therapeutics reported 2Q26 results and highlighted mipletamig's strong frontline AML data, a new CSO appointment, non-dilutive grant funding for APVO451, and a 50/50 Niowave radiopharmaceutical...

APVO

Stock News•2 weeks ago

Vir Biotechnology Q2 Earnings Call Highlights

Vir Biotechnology reported Q2 2026 results, completing enrollment in a key hepatitis delta study and expanding development of prostate cancer candidate VIR-5500, with multiple data readouts planned.

VIR

Stock News•3 weeks ago

HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering

HCW Biologics priced a $1.6M private placement offering at ~$2.59 per unit, issuing 618,682 units to existing investors including officers and directors.

HCWB